TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02563106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYN-004

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04141124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breathing exercise/HRV-biofeedback
Description: 5 min of relaxing breathing, coupled with biological feedback.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Relaxing Breathing
Description: 5 minutes of relaxing breathing guided by a computer helping to follow inspiration and expiration.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: 5 minutes of reading fictitious biological medical results
Study: NCT01557361

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerated RRT initiation
Description: A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of eligibility. This 12 hour window includes the time needed to obtain consent.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard RRT initiation
Description: Patients will be carefully followed over a period of 7 days to identify potential indications for RRT. The trial team will ask that the clinical team consider RRT initiation if there are:~I. Criteria for persistent AKI (serum creatinine has not declined by more than 50% from value recorded at time of eligibility) AND~II. At least one of the following indications for RRT initiation:~1. Serum potassium ≥6.0 mmol/L, or~2. Serum bicarbonate ≤ 10 mmol/L, or~3. Evidence of severe respiratory failure, based on a PaO2/FiO2 \<200 and bilateral infiltrates on the chest x-ray, or~4. By 72 hours after randomization, creatinine has not declined by more than 50% from that recorded at the time of randomization
Study: NCT02418481

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-CIK
Description: DC-CIK cells will be used against tumor cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: γδ T Cell
Description: γδ T cells will be used against breast tumor.
Study: NCT03680105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RJX
Description: RJX is an IV infusion formulation. The appropriate RJX dose is calculated based on mL/kg. The administration dose is prepared by adding the appropriate RJX dose to 0.9% sterile saline such that a constant volume of 100 mL per IV infusion is obtained. Infusion time is 100 mL over 45 minutes (+/- 5 minutes).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be normal saline. To maintain the blind, a sleeve will cover the infusion bag and line such that the appearance will be identical to RJX administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be normal saline. To maintain the blind, a sleeve will cover the infusion bag and line such that the appearance will be identical to RJX administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be normal saline. To maintain the blind, a sleeve will cover the infusion bag and line such that the appearance will be identical to RJX administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be normal saline. To maintain the blind, a sleeve will cover the infusion bag and line such that the appearance will be identical to RJX administration.
Study: NCT00492817

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: On day 1 of radiation treatment, a CT scan using CT-on-Rails in the same treatment room, immediately before the radiation treatment will be performed.
Study: NCT03680105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be normal saline. To maintain the blind, a sleeve will cover the infusion bag and line such that the appearance will be identical to RJX administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be normal saline. To maintain the blind, a sleeve will cover the infusion bag and line such that the appearance will be identical to RJX administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be normal saline. To maintain the blind, a sleeve will cover the infusion bag and line such that the appearance will be identical to RJX administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be normal saline. To maintain the blind, a sleeve will cover the infusion bag and line such that the appearance will be identical to RJX administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be normal saline. To maintain the blind, a sleeve will cover the infusion bag and line such that the appearance will be identical to RJX administration.
Study: NCT01439269

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Nurture Intervention
Description: Family Nurture Intervention is facilitated by specially trained Nurture Specialists. The intervention involves calming interactions between mother and infant in the isolette via odor exchange, firm sustained touch and vocal soothing, through calming interactions during holding and feeding via the Calming Cycle and through family sessions designed to engage the help and support of family members for the mother.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Nurture Intervention
Description: Family Nurture Intervention is facilitated by specially trained Nurture Specialists. The intervention involves calming interactions between mother and infant in the isolette via odor exchange, firm sustained touch and vocal soothing, through calming interactions during holding and feeding via the Calming Cycle and through family sessions designed to engage the help and support of family members for the mother.
Study: NCT03597776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Bolus of lidocaine will be given over 5 minutes before skin incision

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Bolus of saline will be given over 5 minutes before skin incision
Study: NCT04281810

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electric diaphragm stimulation
Description: The electrodes were placed on the parasternal region beside the xiphoid process; and the sixth and seventh intercostal spaces in line with the mid-axillary line. TEDS was set as biphasic waves, frequency of 30 Hz, pulse width of 400 μs, and rise time of 0.7s.
Study: NCT04449900

Intervention type: OTHER
Intervention: This is observational study with the examination of OCTA
Description: This is observational study with the examination of OCTA

Intervention type: OTHER
Intervention: This is observational study with the examination of OCTA
Description: This is observational study with the examination of OCTA
Study: NCT01751178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Digluconate Mouthwash with Alcohol
Description: 0.2% w/v Chlorhexidine Digluconate, alcohol containing - UK Marketed Mouthwash
Study: NCT04007848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib will be given at the dose of 40 milligrams once a day (21 days/28). Cobimetinib is available as 20 milligrams film-coated tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo will be given at the dose of 40 milligrams once a day (21 days/28). Placebo is available as 20 milligrams film-coated tablets
Study: NCT01770093

Intervention type: OTHER
Intervention: Questionnaire
Study: NCT01291511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloperidone
Description: Over-encapsulated iloperidone tablets were administered orally using a bid schedule; the strengths used include 1, 2, 4, 6, 8, 10, and 12 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules were administered orally using a bid schedule during the double-blind period.
Study: NCT03599544

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Robot-Assisted Therapy (RT)
Description: Highly intensive robot-assisted therapy for the paretic arm with the Armeo exoskeleton (1 hour sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo robot (3x week for 3 weeks).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robot + Active Learning Program(RT-ALPS)
Description: Highly intensive robot-assisted therapy for the paretic arm with the Armeo exoskeleton (1 hour sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo robot (3x week for 3 weeks). In addition, participants will receive training in active problem solving, analysis of performance and goal setting focused on home action plan activities to assist with carry-over and generalization to every day activities.
Study: NCT04889690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01804660

Intervention type: OTHER
Intervention: No study treatments administered
Study: NCT01379560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: unoprostone isopropyl
Description: 1. unoprostone isopropyl (2 drops)~2. placebo (2 drops)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: unoprostone isopropyl
Description: 1. unoprostone isopropyl (3 drops)~2. placebo (3 drops)
Study: NCT00723268

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: 5MG Prednisolone per day for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: 0.5 MG Colchicine per day for 3 months
Study: NCT01846689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESS (medical food/drug)
Description: Prescription medical food erythropoietin stimulating system
Study: NCT05911945

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible Ureterorenoscopy
Description: A guidewire was placed in the ureter in the lithotomy position. Ureterorenoscopy was performed with an 8 Fr ureterorenoscope for active dilatation. An 11 - 13 Fr or 9.5 / 11.5 Fr UAS was attempted to be placed under fluoroscopy by the surgeon of the procedure. In cases where the UAS could not inserted, a 26 cm, 4.8 Fr JJ stent was placed under fluoroscopy and the procedure was terminated. Patients underwent a second f-URS session, 4 - 6 weeks later. After the JJ stent was removed, an 11 - 13 Fr UAS was placed in the ureter. Digital flexible ureterorenoscope was used as the flexible ureteroscope. Stone fragmentation was performed in dusting mode using a Ho:YAG laser with a 272 µ probe. After fragmentation, a 26 cm 4.8 Fr JJ stent was inserted into the ureter. The JJ stent was removed at 4 - 6 weeks postoperatively.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mini Percutaneous Nephrolithotomy
Description: A guidewire was placed in the ureter in the lithotomy position. Ureterorenoscopy was performed with an 8 Fr ureterorenoscope for active dilatation. An 11 - 13 Fr or 9.5 / 11.5 Fr UAS was attempted to be placed under fluoroscopy by the surgeon of the procedure. In cases where the UAS could not inserted, patients were positioned in prone position and access was performed to the appropriate calyx with an 18-gauge percutaneous access needle using the triangulation technique accompanied by fluoroscopy, in the same session. After the guidewire was introduced into the pelvicalyceal system, sequential dilatation was applied with Amplatz dilatators, and a 21 Fr metallic sheath was placed. Stones were fragmented with a yttrium-aluminum-garnet (Ho:YAG) Laser lithotripter. At the end of the procedure, a 14 Fr nephrostomy catheter was placed in according to the residual stone, hemorrhage, and perforation status. In other cases, the procedure was concluded as totally tubeless.
Study: NCT00476398

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Capsule endoscopy
Description: Patient will undergo a capsule endoscopy for the evaluation of their chest pain.
Study: NCT01929018

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise will target muscle strength and joint mobility impairments and will be delivered over a 12 week period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking Program
Description: A walking program will be established with the goal of participants walking at least five days per week. Duration of program is 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Self-Management Support
Description: Health self-management support will be delivered with weekly meetings between the researcher and participant over a 12-week period.
Study: NCT03996889

Intervention type: DEVICE
Intervention: Endovascular treatment of aneurysms of the popliteal artery by GORE VIABAHN® stent in elective surgery
Description: The intervention can be performed under local anesthesia (LA), regional locus (ALR) or general anesthesia (AG) (data collected) by first approach: percutaneous or conventional.~The data collected are:~* Number of GORE VIABAHN® stent used (length and diameter of each)~* Embolization of collaterals and other related actions~* Operative complications~* Intraoperative fibrinolysis~* Collar cover\> 2 cm~* Lack of overlap in the overlap zone (nb: between 4 and 8 cm above the joint spacing)~* Arteriography in profile, kink
Study: NCT00069017

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MEDI-522
Description: MEDI-522 is formulated in a sterile isotonic solution of 10 mM histidine-HCl at pH 6 containing 100 mg of MEDI-522 protein at a concentration of 100 mg/mL.
Study: NCT01751178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Digluconate Mouthwash without Alcohol
Description: 0.2% w/v Chlorhexidine Digluconate, without alcohol - UK Marketed Mouthwash
Study: NCT03374397

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Surgiguard
Description: Hemostasis with Surgiguard during laparoscopic unilateral ovarian cystectomy
Study: NCT00069017

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for MEDI-522 contains 10 mM histidine-HCl at pH 6, 0.1% Tween-80, 1.5% Mannitol, 4.3 µg/mL Vitamin B12, and 2 µg/mL D\&C Yellow #10.
Study: NCT04762784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab treatment: Tocilizumab infusion 8mg/Kg，Once per month for 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoids
Description: Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks to equal to or less than 15mg per day in 3 months.
Study: NCT02385500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Description: For each phase of the study, the participants will receive a total of 84 pills of fesoterodine 4 mg. The study medication will be provided by Pfizer.~For blinded distribution, each bottle of medications will be labeled with a random number for identification. The participant will indicate in a journal the dose taken each day.~The study participants will be monitored every 2 weeks with phone calls to assess tolerance or side-effects to the medication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fesoterodine
Description: For each phase of the study, the participants will receive a total of 84 pills of fesoterodine 4 mg. The study medication will be provided by Pfizer.~For blinded distribution, each bottle of medications will be labeled with a random number for identification. The participant will indicate in a journal the dose taken each day.~The study participants will be monitored every 2 weeks with phone calls to assess tolerance or side-effects to the medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: For each phase of the study, the participants will receive a total of 84 placebo pills. The study medication will be provided by Pfizer.~For blinded distribution, each bottle of medications will be labeled with a random number for identification. The participant will indicate in a journal the dose taken each day.~The study participants will be monitored every 2 weeks with phone calls to assess tolerance or side-effects to the medication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For each phase of the study, the participants will receive a total of 84 placebo pills. The study medication will be provided by Pfizer.~For blinded distribution, each bottle of medications will be labeled with a random number for identification. The participant will indicate in a journal the dose taken each day.~The study participants will be monitored every 2 weeks with phone calls to assess tolerance or side-effects to the medication.
Study: NCT02587260

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence
Study: NCT03193944

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-vitin, soft gelatin capsule (vitamin D3,50000 IU)
Description: Intervention group: The respondents in intervention group will receive 50000 vitamin D for 8 weeks. Plus, brochures and pamphlets related to nutrition and health.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vitamin D3
Description: vitamin D as a placebo
Study: NCT03348813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV/STI Prevention Intervention
Description: The targeted HIV/STI risk reduction intervention was delivered with groups of up to 8 participants through 8, 45-minute modules equally divided over 2 days (4 modules per session). It was designed to enhance participants' knowledge and ability to reduce their risk of HIV/STIs. Grounded in both social/behavioral and cognitive theories, the intervention includes psychoeducation, and was intended to enhance participants' HIV/STI prevention knowledge, attitudes, beliefs and skills in a manner relevant to Black adolescents.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Health Control Intervention
Description: The original Promoting Health among Teens (PHAT) Project was designed to increase knowledge and motivation regarding healthful dietary practices, aerobic exercise, and breast and testicular self-examination, and to discourage cigarette smoking. The 8-hour, 2-session PHAT intervention was shortened to mirror the Project GOLD HIV/STI risk reduction curriculum. This was done to control for the Hawthorne effect and reduce the likelihood that effects of the HIV/STI risk reduction intervention can be attributed to its nonspecific features, including special attention. From an ethical standpoint, adolescents in both conditions received a valuable and engaging health-risk-reduction intervention as opposed to usual care.
Study: NCT02587260

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence
Study: NCT02418481

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combination
Description: γδ T/DC-CIK cells will be used against breast tumor.
Study: NCT01118286

Intervention type: DRUG
Intervention: Nifedipine (Adalat, BAYA1040)
Description: Previously untreated hypertensive adult patients starting with combination therapy containing nifedipine or insufficiently controlled hypertensive patients receiving nifedipine as an add-on to existing non-CCB containing antihypertensive therapy. The decision of including the patient as well as decision on dosage and duration is taken by the investigator.
Study: NCT02587260

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence